{"id":"trastuzumab-emtansine-t-dm1","safety":{"commonSideEffects":[{"effect":"Nausea","drugRate":"60.6%","placeboRate":"","totalAtRisk":2272,"totalAffected":1377,"trialsReporting":8},{"effect":"Alopecia","drugRate":"59.2%","placeboRate":"","totalAtRisk":2272,"totalAffected":1346,"trialsReporting":8},{"effect":"Diarrhoea","drugRate":"56.1%","placeboRate":"","totalAtRisk":2272,"totalAffected":1274,"trialsReporting":8},{"effect":"Fatigue","drugRate":"40.6%","placeboRate":"","totalAtRisk":2272,"totalAffected":922,"trialsReporting":8},{"effect":"FATIGUE","drugRate":"29.4%","placeboRate":"","totalAtRisk":2722,"totalAffected":799,"trialsReporting":2},{"effect":"NAUSEA","drugRate":"27.3%","placeboRate":"","totalAtRisk":2722,"totalAffected":744,"trialsReporting":2},{"effect":"Vomiting","drugRate":"28.0%","placeboRate":"","totalAtRisk":2272,"totalAffected":637,"trialsReporting":8},{"effect":"Constipation","drugRate":"27.8%","placeboRate":"","totalAtRisk":2272,"totalAffected":632,"trialsReporting":8},{"effect":"Anaemia","drugRate":"26.3%","placeboRate":"","totalAtRisk":2272,"totalAffected":597,"trialsReporting":8},{"effect":"HEADACHE","drugRate":"21.2%","placeboRate":"","totalAtRisk":2722,"totalAffected":578,"trialsReporting":2},{"effect":"Arthralgia","drugRate":"23.7%","placeboRate":"","totalAtRisk":2272,"totalAffected":538,"trialsReporting":8},{"effect":"Neutropenia","drugRate":"23.1%","placeboRate":"","totalAtRisk":2243,"totalAffected":518,"trialsReporting":6},{"effect":"Headache","drugRate":"22.1%","placeboRate":"","totalAtRisk":2272,"totalAffected":502,"trialsReporting":8},{"effect":"Stomatitis","drugRate":"21.8%","placeboRate":"","totalAtRisk":2272,"totalAffected":495,"trialsReporting":8},{"effect":"Rash","drugRate":"21.7%","placeboRate":"","totalAtRisk":2272,"totalAffected":493,"trialsReporting":8},{"effect":"ASTHENIA","drugRate":"24.5%","placeboRate":"","totalAtRisk":2002,"totalAffected":491,"trialsReporting":1},{"effect":"CONSTIPATION","drugRate":"16.6%","placeboRate":"","totalAtRisk":2722,"totalAffected":453,"trialsReporting":2},{"effect":"Asthenia","drugRate":"19.9%","placeboRate":"","totalAtRisk":2272,"totalAffected":451,"trialsReporting":8},{"effect":"EPISTAXIS","drugRate":"15.7%","placeboRate":"","totalAtRisk":2722,"totalAffected":427,"trialsReporting":2},{"effect":"ARTHRALGIA","drugRate":"15.5%","placeboRate":"","totalAtRisk":2722,"totalAffected":423,"trialsReporting":2},{"effect":"Decreased appetite","drugRate":"22.6%","placeboRate":"","totalAtRisk":1868,"totalAffected":423,"trialsReporting":7},{"effect":"Myalgia","drugRate":"18.3%","placeboRate":"","totalAtRisk":2272,"totalAffected":416,"trialsReporting":8},{"effect":"Pyrexia","drugRate":"16.3%","placeboRate":"","totalAtRisk":2272,"totalAffected":371,"trialsReporting":8},{"effect":"PYREXIA","drugRate":"13.5%","placeboRate":"","totalAtRisk":2722,"totalAffected":368,"trialsReporting":2},{"effect":"Peripheral sensory neuropathy","drugRate":"19.7%","placeboRate":"","totalAtRisk":1868,"totalAffected":368,"trialsReporting":7},{"effect":"Dysgeusia","drugRate":"16.0%","placeboRate":"","totalAtRisk":2272,"totalAffected":364,"trialsReporting":8},{"effect":"Neuropathy peripheral","drugRate":"18.7%","placeboRate":"","totalAtRisk":1868,"totalAffected":350,"trialsReporting":7},{"effect":"Cough","drugRate":"15.3%","placeboRate":"","totalAtRisk":2272,"totalAffected":347,"trialsReporting":8},{"effect":"DIARRHOEA","drugRate":"12.5%","placeboRate":"","totalAtRisk":2722,"totalAffected":341,"trialsReporting":2},{"effect":"DECREASED APPETITE","drugRate":"12.3%","placeboRate":"","totalAtRisk":2722,"totalAffected":336,"trialsReporting":2},{"effect":"Epistaxis","drugRate":"14.7%","placeboRate":"","totalAtRisk":2272,"totalAffected":334,"trialsReporting":8},{"effect":"VOMITING","drugRate":"12.2%","placeboRate":"","totalAtRisk":2722,"totalAffected":331,"trialsReporting":2},{"effect":"Insomnia","drugRate":"14.5%","placeboRate":"","totalAtRisk":2272,"totalAffected":329,"trialsReporting":8},{"effect":"Oedema peripheral","drugRate":"16.6%","placeboRate":"","totalAtRisk":1868,"totalAffected":310,"trialsReporting":7},{"effect":"COUGH","drugRate":"11.2%","placeboRate":"","totalAtRisk":2722,"totalAffected":306,"trialsReporting":2},{"effect":"Radiation skin injury","drugRate":"20.5%","placeboRate":"","totalAtRisk":1486,"totalAffected":305,"trialsReporting":4},{"effect":"Pruritus","drugRate":"13.1%","placeboRate":"","totalAtRisk":2272,"totalAffected":297,"trialsReporting":8},{"effect":"DRY MOUTH","drugRate":"10.7%","placeboRate":"","totalAtRisk":2722,"totalAffected":292,"trialsReporting":2},{"effect":"Nasopharyngitis","drugRate":"13.5%","placeboRate":"","totalAtRisk":2131,"totalAffected":287,"trialsReporting":6},{"effect":"MYALGIA","drugRate":"10.5%","placeboRate":"","totalAtRisk":2722,"totalAffected":285,"trialsReporting":2},{"effect":"Mucosal inflammation","drugRate":"15.1%","placeboRate":"","totalAtRisk":1839,"totalAffected":277,"trialsReporting":5},{"effect":"Hot flush","drugRate":"14.3%","placeboRate":"","totalAtRisk":1868,"totalAffected":268,"trialsReporting":7},{"effect":"BACK PAIN","drugRate":"9.7%","placeboRate":"","totalAtRisk":2722,"totalAffected":265,"trialsReporting":2},{"effect":"Dyspepsia","drugRate":"11.7%","placeboRate":"","totalAtRisk":2272,"totalAffected":265,"trialsReporting":8},{"effect":"DYSPNOEA","drugRate":"9.7%","placeboRate":"","totalAtRisk":2722,"totalAffected":263,"trialsReporting":2},{"effect":"Dizziness","drugRate":"10.7%","placeboRate":"","totalAtRisk":2272,"totalAffected":242,"trialsReporting":8},{"effect":"ANAEMIA","drugRate":"8.6%","placeboRate":"","totalAtRisk":2722,"totalAffected":233,"trialsReporting":2},{"effect":"Upper respiratory tract infection","drugRate":"12.5%","placeboRate":"","totalAtRisk":1868,"totalAffected":233,"trialsReporting":7},{"effect":"Alanine aminotransferase increased","drugRate":"14.9%","placeboRate":"","totalAtRisk":1515,"totalAffected":226,"trialsReporting":6},{"effect":"PAIN IN EXTREMITY","drugRate":"8.0%","placeboRate":"","totalAtRisk":2722,"totalAffected":219,"trialsReporting":2}]},"_chembl":{"chemblId":"CHEMBL1743082","moleculeType":"Antibody drug conjugate"},"allNames":"trastuzumab emtansine (t-dm1)","_dailymed":null,"mechanism":{"target":"HER2","drugClass":"Antibody-drug conjugate","explanation":"Trastuzumab emtansine binds to the HER2 receptor on cancer cells, which triggers the release of a chemotherapy drug inside the cell, leading to cell death. This targeted approach minimizes damage to healthy cells.","oneSentence":"Trastuzumab emtansine targets HER2-positive cancer cells, delivering a cytotoxic payload that inhibits cell growth and induces apoptosis."},"_scrapedAt":"2026-03-28T01:47:40.387Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:45:54.133752+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT04158258","phase":"","title":"A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-02-21","conditions":"Breast Cancer","enrollment":2907},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT06324357","phase":"PHASE1, PHASE2","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-06-03","conditions":"Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":768},{"nctId":"NCT05323955","phase":"PHASE2","title":"Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Carey Anders, M.D.","startDate":"2023-03-23","conditions":"Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer","enrollment":48},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT04589845","phase":"PHASE2","title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-01-18","conditions":"Solid Tumors","enrollment":920},{"nctId":"NCT02675829","phase":"PHASE2","title":"Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-02","conditions":"Solid Tumor Cancers, Lung Cancer, Bladder Cancer","enrollment":131},{"nctId":"NCT04873362","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-04","conditions":"Breast Cancer","enrollment":1188},{"nctId":"NCT07421141","phase":"PHASE2","title":"De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Radiological Centre of the Ministry of Health of Russia","startDate":"2023-09-01","conditions":"Breast Cancer, HER2-positive Breast Cancer, Early Breast Cancer","enrollment":186},{"nctId":"NCT03523585","phase":"PHASE3","title":"DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-08-01","conditions":"Breast Cancer","enrollment":608},{"nctId":"NCT05593094","phase":"PHASE1, PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":"Advanced Solid Tumors, HER2-positive Breast Cancer","enrollment":210},{"nctId":"NCT04893109","phase":"PHASE2","title":"ATEMPT 2.0: Adjuvant T-DM1 vs TH","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-06-16","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":500},{"nctId":"NCT05081609","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Oncology Division A/S","startDate":"2022-01-11","conditions":"Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":320},{"nctId":"NCT04620187","phase":"PHASE2","title":"Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-12-24","conditions":"Salivary Gland Cancer, HER2 Gene Mutation","enrollment":55},{"nctId":"NCT06446882","phase":"NA","title":"Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Fundacio Clinic Barcelona","startDate":"2024-10-11","conditions":"HER2-positive Breast Cancer, Early-stage Breast Cancer","enrollment":304},{"nctId":"NCT01853748","phase":"PHASE2","title":"T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-05","conditions":"Breast Cancer","enrollment":512},{"nctId":"NCT06595563","phase":"PHASE2","title":"HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2026-02","conditions":"HER2-positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer","enrollment":87},{"nctId":"NCT03587740","phase":"PHASE2","title":"ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-08-22","conditions":"Breast Cancer","enrollment":82},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT02226276","phase":"NA","title":"Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2015-01-07","conditions":"Bone Metastases, HER2-positive Breast Cancer, Liver Metastases","enrollment":10},{"nctId":"NCT06068985","phase":"PHASE2","title":"Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"Latin American Cooperative Oncology Group","startDate":"2024-09-05","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":63},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT07389876","phase":"","title":"Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Gastric Cancer, Second-line Treatment","enrollment":250},{"nctId":"NCT06828588","phase":"EARLY_PHASE1","title":"Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2026-02","conditions":"Locally Advanced Cancer, Metastatic Cancer, HER2","enrollment":30},{"nctId":"NCT01494662","phase":"PHASE2","title":"HKI-272 for HER2-Positive Breast Cancer and Brain Metastases","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-02","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT06830889","phase":"PHASE3","title":"A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-06-03","conditions":"HER2-positive Breast Cancer","enrollment":1450},{"nctId":"NCT05673928","phase":"PHASE2","title":"A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-05-16","conditions":"Metastatic Solid Tumor, Brain Metastases","enrollment":30},{"nctId":"NCT05408845","phase":"PHASE2","title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-03-03","conditions":"Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8","enrollment":146},{"nctId":"NCT07126561","phase":"PHASE2","title":"Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-11-01","conditions":"HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2","enrollment":43},{"nctId":"NCT04578106","phase":"PHASE2","title":"Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy","status":"TERMINATED","sponsor":"Fundacio Clinic Barcelona","startDate":"2020-09-23","conditions":"HER2-positive Breast Cancer, Stage I Breast Cancer","enrollment":5},{"nctId":"NCT00781612","phase":"PHASE2","title":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2008-10-16","conditions":"Neoplasm Metastasis","enrollment":720},{"nctId":"NCT03975647","phase":"PHASE3","title":"A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2019-10-02","conditions":"HER2-positive Breast Cancer","enrollment":466},{"nctId":"NCT07259226","phase":"PHASE2","title":"Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-14","conditions":"Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer","enrollment":400},{"nctId":"NCT07257809","phase":"PHASE2","title":"Herombopag Treated T-DM1 Induced Platelet Reduction","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-10-13","conditions":"Thrombocytopenia","enrollment":56},{"nctId":"NCT06663787","phase":"","title":"Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nagoya City University","startDate":"2024-04-01","conditions":"Breast Cancer, Metastatic, HER2 + Breast Cancer","enrollment":50},{"nctId":"NCT01975142","phase":"PHASE2","title":"Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2013-11-07","conditions":"Metastatic Breast Cancer, HER2 Negative Primary Tumor","enrollment":155},{"nctId":"NCT04439110","phase":"PHASE2","title":"Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-12","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":38},{"nctId":"NCT04733118","phase":"PHASE2","title":"Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2021-08-05","conditions":"Early Breast Cancer","enrollment":393},{"nctId":"NCT05889988","phase":"","title":"A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-06-12","conditions":"Breast Neoplasm","enrollment":36},{"nctId":"NCT04042701","phase":"PHASE1","title":"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2020-02-10","conditions":"Breast Cancer, Non-small Cell Lung Carcinoma","enrollment":115},{"nctId":"NCT04457596","phase":"PHASE3","title":"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-03-02","conditions":"Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8","enrollment":1056},{"nctId":"NCT03529110","phase":"PHASE3","title":"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-09","conditions":"Breast Cancer","enrollment":524},{"nctId":"NCT06265428","phase":"PHASE3","title":"A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-01-29","conditions":"HER2-positive Breast Cancer","enrollment":228},{"nctId":"NCT04419181","phase":"PHASE2","title":"Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer","status":"WITHDRAWN","sponsor":"University of Rochester","startDate":"2025-08-11","conditions":"HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT05945927","phase":"","title":"A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2023-09-13","conditions":"Breast Cancer","enrollment":178},{"nctId":"NCT07198672","phase":"NA","title":"Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag","status":"NOT_YET_RECRUITING","sponsor":"Zhenzhen Liu","startDate":"2025-10-31","conditions":"HER2-positive Breast Cancer","enrollment":45},{"nctId":"NCT03820063","phase":"PHASE2","title":"Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Borstkanker Onderzoek Groep","startDate":"2019-02-27","conditions":"Breast Cancer","enrollment":462},{"nctId":"NCT04486352","phase":"PHASE1, PHASE2","title":"A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer","status":"RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2021-10-20","conditions":"Endometrial Cancer","enrollment":148},{"nctId":"NCT06316531","phase":"PHASE3","title":"A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-05-08","conditions":"HER2-positive Breast Cancer","enrollment":274},{"nctId":"NCT07008976","phase":"PHASE3","title":"Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-07","conditions":"Metastatic Breast Cancer","enrollment":246},{"nctId":"NCT04740918","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-06-07","conditions":"Metastatic Breast Cancer","enrollment":96},{"nctId":"NCT04341181","phase":"PHASE2","title":"ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling","status":"RECRUITING","sponsor":"Ulrik Lassen","startDate":"2020-08-24","conditions":"Cancer, Tumors, Neoplasms","enrollment":300},{"nctId":"NCT04042051","phase":"PHASE1","title":"Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","status":"TERMINATED","sponsor":"Cancer Trials Ireland","startDate":"2019-11-12","conditions":"HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer","enrollment":2},{"nctId":"NCT01772472","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-04-03","conditions":"Breast Cancer","enrollment":1486},{"nctId":"NCT05650879","phase":"PHASE1","title":"ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enliven Therapeutics","startDate":"2023-03-20","conditions":"HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation","enrollment":198},{"nctId":"NCT03248492","phase":"PHASE2","title":"A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2017-08-25","conditions":"Breast Cancer","enrollment":253},{"nctId":"NCT06439693","phase":"PHASE2","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-08","conditions":"Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic","enrollment":72},{"nctId":"NCT07021911","phase":"","title":"Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Campus Bio-Medico","startDate":"2023-05-17","conditions":"Breast Cancer, Radiotherapy; Complications","enrollment":300},{"nctId":"NCT02314481","phase":"PHASE2","title":"Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2017-05-12","conditions":"Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT06968585","phase":"PHASE3","title":"A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2023-07-18","conditions":"HER2-positive Breast Cancer","enrollment":365},{"nctId":"NCT04622319","phase":"PHASE3","title":"A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2020-12-04","conditions":"HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer","enrollment":1600},{"nctId":"NCT06126640","phase":"PHASE3","title":"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-11-20","conditions":"HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","enrollment":1600},{"nctId":"NCT06643585","phase":"PHASE3","title":"A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse","status":"RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2025-04-22","conditions":"Breast Cancer","enrollment":180},{"nctId":"NCT05525858","phase":"","title":"KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2022-09-28","conditions":"Solid Tumor, Advanced Solid Tumor, Metastatic Cancer","enrollment":1000},{"nctId":"NCT05288777","phase":"PHASE2, PHASE3","title":"Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2022-07-11","conditions":"Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II","enrollment":45},{"nctId":"NCT06928818","phase":"","title":"Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-02-26","conditions":"Cancer of Breast, Trastuzumab Emtansine, Trastuzumab Deruxtecan","enrollment":100},{"nctId":"NCT04680442","phase":"PHASE2","title":"Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-01","conditions":"Breast Cancer, Heart Failure","enrollment":130},{"nctId":"NCT04509596","phase":"PHASE1","title":"DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer","status":"COMPLETED","sponsor":"Dizal Pharmaceuticals","startDate":"2020-09-21","conditions":"Breast Cancer Metastatic","enrollment":23},{"nctId":"NCT01565200","phase":"PHASE2","title":"HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2012-05","conditions":"HER-2 Positive Breast Cancer","enrollment":90},{"nctId":"NCT06846437","phase":"PHASE3","title":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-02-18","conditions":"Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants","enrollment":228},{"nctId":"NCT06877416","phase":"","title":"Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-01-01","conditions":"Antibody-drug Conjugates, HER2-low Breast Cancer, Breast Neoplasms","enrollment":700},{"nctId":"NCT02326974","phase":"PHASE2","title":"T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-01","conditions":"HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer","enrollment":164},{"nctId":"NCT01745965","phase":"PHASE2","title":"A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2012-11","conditions":"Breast Cancer","enrollment":380},{"nctId":"NCT06839547","phase":"","title":"A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug As a Radiosensitizer in Patients with Advanced Breast Cancer Brain Metastasis.","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-03-01","conditions":"Advanced Breast Cancer Brain Metastasis","enrollment":100},{"nctId":"NCT06450314","phase":"PHASE2","title":"Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-01-25","conditions":"Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":170},{"nctId":"NCT05388149","phase":"PHASE2","title":"Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-12-06","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":15},{"nctId":"NCT03523572","phase":"PHASE1","title":"Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-08-02","conditions":"Breast Cancer, Urothelial Carcinoma","enrollment":86},{"nctId":"NCT03032107","phase":"PHASE1","title":"A Study Of Pembrolizumab In Combination With Trastuzumab-DM1","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-02-17","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT04632992","phase":"PHASE2","title":"A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2021-01-13","conditions":"Advanced Unresectable or Metastatic Solid Malignancy","enrollment":252},{"nctId":"NCT06718335","phase":"NA","title":"Pyrotinib in HER2-positive Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nie Jianyun","startDate":"2024-12-30","conditions":"HER2-positive Breast Cancer","enrollment":156},{"nctId":"NCT04675827","phase":"PHASE2","title":"De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2022-01-17","conditions":"HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer","enrollment":139},{"nctId":"NCT06693037","phase":"","title":"Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Shu Wang","startDate":"2019-01-01","conditions":"HER2-positive Breast Cancer","enrollment":2092},{"nctId":"NCT03726879","phase":"PHASE3","title":"A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-01-11","conditions":"Breast Cancer","enrollment":454},{"nctId":"NCT02390427","phase":"PHASE1","title":"Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Otto Metzger, MD","startDate":"2015-04-20","conditions":"Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":68},{"nctId":"NCT06272799","phase":"","title":"Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.","status":"RECRUITING","sponsor":"Regina Elena Cancer Institute","startDate":"2022-09-20","conditions":"Breast Cancer","enrollment":160},{"nctId":"NCT03530696","phase":"PHASE2","title":"T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2018-12-06","conditions":"HER2-positive Breast Cancer, Breast Cancer, Breast Cancer Stage","enrollment":55},{"nctId":"NCT06481956","phase":"PHASE2","title":"T-DM1 Combined With CDK4/6 Inhibitor Ribociclib","status":"ENROLLING_BY_INVITATION","sponsor":"Zheng Yabing","startDate":"2023-10-25","conditions":"HER2-positive Advanced Breast Cancer","enrollment":40},{"nctId":"NCT06313086","phase":"PHASE3","title":"DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-03-13","conditions":"HER2-positive Breast Cancer","enrollment":442},{"nctId":"NCT02448420","phase":"PHASE2","title":"Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2015-07","conditions":"Metastatic Breast Cancer","enrollment":73},{"nctId":"NCT06125834","phase":"PHASE2","title":"Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-06-01","conditions":"Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine","enrollment":36},{"nctId":"NCT06299852","phase":"NA","title":"Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer","status":"UNKNOWN","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2022-07-01","conditions":"HER2-positive Metastatic Breast Cancer, Oligometastatic Disease","enrollment":58},{"nctId":"NCT03709082","phase":"PHASE1, PHASE2","title":"Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer","status":"TERMINATED","sponsor":"University of Kansas Medical Center","startDate":"2018-10-15","conditions":"HER2-positive Breast Cancer, Breast Cancer Metastatic","enrollment":3},{"nctId":"NCT01120184","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-07-31","conditions":"Breast Cancer","enrollment":1095},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT03894410","phase":"","title":"Real World Study of Lapatinib Among Metastatic Breast Cancer Patients","status":"COMPLETED","sponsor":"Fudan University","startDate":"2019-01-10","conditions":"Breast Cancer","enrollment":242},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT02564900","phase":"PHASE1","title":"Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2015-09-01","conditions":"Advanced Solid Tumors","enrollment":292},{"nctId":"NCT04197687","phase":"PHASE2","title":"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery","status":"UNKNOWN","sponsor":"Academic and Community Cancer Research United","startDate":"2020-02-20","conditions":"Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7","enrollment":480}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BUNDLE BRANCH BLOCK LEFT"},{"count":1,"reaction":"CARDIAC FAILURE"},{"count":1,"reaction":"CARDIOTOXICITY"},{"count":1,"reaction":"LEFT VENTRICULAR DYSFUNCTION"}],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Trastuzumab Emtansine (T-DM1)","genericName":"trastuzumab-emtansine-t-dm1","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":8,"trialStats":{"total":17,"withResults":10},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:45:54.133752+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}